What This Trial Looked At
Many people who recover from the acute phase of COVID-19 are left, for weeks afterward, with breathlessness, fatigue and a sense that their lungs and legs no longer cooperate the way they used to. Rehabilitation in this early window matters, because how well someone moves and breathes in the first month often shapes the pace of their wider recovery. Researchers in the Czech Republic asked a focused question: could inhaling molecular hydrogen — a gas studied for its antioxidant and anti-inflammatory properties — help restore physical and respiratory function during this fragile post-infection period?
To test this, they ran a randomised, single-blind, placebo-controlled trial in 50 adults who were recovering from COVID-19, recruited roughly three to four weeks after a positive test. Half inhaled hydrogen and half inhaled an inactive placebo gas, for two one-hour sessions a day across 14 days. “Single-blind” means the participants did not know which gas they were receiving, though the researchers did. Before and after the two weeks, everyone completed a six-minute walking test — a standard, real-world measure of stamina — and breathing tests that gauge how much air the lungs can hold and how forcefully it can be exhaled.
What They Found
The clearest result was in walking distance. After 14 days, the hydrogen group could walk about 64 metres further in six minutes than they had at the start, compared with the placebo group — a meaningful jump in everyday endurance for people who had recently been short of breath crossing a room.
Lung function moved in the same direction. The hydrogen group showed measurable gains in forced vital capacity (the total volume of air they could exhale after a deep breath) and in the amount of air they could push out in the first second of that breath. The improvements over placebo were modest in absolute terms but statistically reliable, and the two changes tracked together: people whose breathing improved also tended to be the ones whose walking improved.
The authors reported no safety concerns over the two weeks of twice-daily sessions, which is consistent with the broader safety record of inhaled hydrogen in clinical studies.
What This Means in Context
This is a genuine randomised controlled trial with a placebo arm, which puts it on firmer ground than an observational study. That said, the results deserve a measured reading. Fifty participants is a small group, the trial was single-blind rather than fully double-blind, and it captured only a narrow slice of time — the acute window a few weeks after infection — so it cannot tell us whether the gains hold over months or apply to people with long-standing post-COVID symptoms.
It is best seen as an early, encouraging signal rather than a settled conclusion. It fits a wider pattern in respiratory research where hydrogen has shown supportive effects on inflammation and recovery, but confirming whether those effects translate into durable clinical benefit will require larger, double-blind trials with longer follow-up. Until then, the honest framing is that this is one promising piece of a still-incomplete picture.
What It Means for You
If you are recovering from a respiratory illness and feeling the lingering drag on your breathing and stamina, this trial offers a reasonable basis for curiosity about hydrogen inhalation as a supportive measure alongside conventional rehabilitation — not as a replacement for it. The intervention here was structured and consistent: twice-daily sessions over two weeks, not occasional use.
Recovery after COVID-19 varies enormously from person to person, and what helped this group may not map neatly onto your situation. Before adding hydrogen inhalation to a recovery plan, talk it through with the clinician who is managing your care, so it fits safely with the rest of your treatment.
Botek, M., Krejčí, J., Valenta, M., McKune, A., Sládečková, B., Konečný, P., Klimešová, I., & Pastucha, D. (2022). Molecular Hydrogen Positively Affects Physical and Respiratory Function in Acute Post-COVID-19 Patients: A New Perspective in Rehabilitation. International Journal of Environmental Research and Public Health, 19(4), 1992. PMID: 35206179.
